When it comes to fighting cancer,
early detection matters.

Our mission at PROMISS® Diagnostics is to provide a globally accessible, non-invasive and precise diagnostic test for ovarian cancer.

Detecting Cancer Early

Ovarian cancer causes more deaths than any other cancer of the female reproductive system in the United States. 1 in 79 women develops ovarian cancer in her lifetime and 54% will die within five years. This high fatality is due in part to a lack of highly efficacious and readily accessible diagnostic tools to detect ovarian cancer at early stages when survival is high.

At PROMISS® Diagnostics, we aim to help clinicians detect ovarian cancer early, while lowering costs and improving patient outcomes. That's why we developed PROMISS -- an innovative, non-invasive ovarian cancer diagnostic test that brings certainty for patients and clinicians.

17%

Rate of survival for ovarian cancer diagnosed at stage four

#1

Mortality among all gynecologic cancers

5 Times

Increased survival when caught at stage one vs. stage four

Our Technology

Learn about our non-invasive patented technology that provides more certainty to women and clinicians when it comes to ovarian cancer.

Learn More

Our Team

Meet the people behind the passion and vision of PROMISS, all dedicated to helping women worldwide fight cancer with early detection.

Learn More

Our Value

We solve the unmet needs of an untapped $2 billion market and create value for patients, payers, and healthcare providers.


Learn More